Insulin savings available for people with commercial insurance and the uninsured by calling (833) 808-1234 INDIANAPOLIS , April 7, 2020 /PRNewswire/ -- In response to the crisis caused by COVID-19, Eli Lilly and Company (NYSE: LLY) is introducing the Lilly Insulin Value Program, allowing anyone

-- Taltz is the first and only IL-17A antagonist approved to treat this population -- INDIANAPOLIS , March 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for

INDIANAPOLIS , March 24, 2020 /PRNewswire/ -- To keep the diabetes community informed about important developments from the COVID-19 crisis, Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3 , Lilly does not

RIDGEFIELD, Conn. and INDIANAPOLIS, March 20, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1

Recognition reinforces baricitinib's potential to be the first FDA-approved medicine for individuals living with alopecia areata INDIANAPOLIS , March 16, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S.

-- FDA Fast Track designation is for the investigation of potential new therapies that treat serious conditions and fulfill an unmet medical need RIDGEFIELD, Conn. and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the

Participation Adds to Lilly's Suite of Affordability Solutions INDIANAPOLIS , March 11, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) is proud to announce its planned participation in the new Part D Senior Savings Model, announced today by the Centers for Medicare & Medicaid Services

NEW YORK and INDIANAPOLIS , March 2, 2020 /PRNewswire/ --  Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC),

INDIANAPOLIS, February 28, 2020 – Eli Lilly and Company shared the following statement in response to the Institute for Clinical and Economic Review (ICER) Final Report on Acute Treatments for Migraine: Effectiveness and Value. Lilly appreciates the recognition the ICER report brings to the need

Regulatory submission based on the positive Phase 3 RELAY study of CYRAMZA in combination with erlotinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations INDIANAPOLIS , Feb. 26, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: